AZ reveals another Phase III selumetinib miss

AstraZeneca plc (LSE:AZN; NYSE:AZN) disclosed in its 2Q18 earnings that it discontinued development of selumetinib to treat differentiated thyroid cancer after the candidate missed the primary endpoint in the Phase III ASTRA trial in the indication. In the 233-patient trial,

Read the full 406 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE